Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Global Randomized Phase 1b/2 Clinical Study to Evaluate TPST-1120 in Combination with the Standard-of-Care First-Line Regimen of Atezolizumab and Bevacizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) not Previously Treated with Systemic Therapy

Next Previous
Trial Profile

A Global Randomized Phase 1b/2 Clinical Study to Evaluate TPST-1120 in Combination with the Standard-of-Care First-Line Regimen of Atezolizumab and Bevacizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma (HCC) not Previously Treated with Systemic Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amezalpat (Primary) ; Atezolizumab; Bevacizumab
  • Indications Liver cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 05 Jun 2025 According to a Tempest Therapeutics media release, company announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), for the treatment of patients with hepatocellular carcinoma.
  • 10 Feb 2025 According to a Tempest Therapeutics media release, company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to amezalpat (TPST-1120), an oral, small molecule, selective PPAR antagonist for the treatment of patients with hepatocellular carcinoma (HCC).
  • 15 Aug 2024 According to a Tempest Therapeutics media release, the company announced positive feedback from its end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab to treat first-line unresectable or metastatic hepatocellular carcinoma (HCC).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top